Anyone speak to the CEO?
on Feb 28 this is a response i got about whay theyre working on: Over the next few months, we will focus on advancing our liver program, continue licensing discussions with Wisconsin for the transdermal delivery technology and start formulation and stability work, further identify technology to track patient data (structured and unstructured) and look to machine learning opp. Evaluate OTC and prescription products and seek supply from LP's.